Nikem Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 22 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.16 Cr
- Satisfied Charges ₹ 4.95 M
- Revenue Growth 20.74%
- Profit Growth 98.89%
- Ebitda 154.86%
- Net Worth 37.72%
- Total Assets 11.53%
About Nikem Drugs
Nikem Drugs Private Limited (NDPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 30 December 2002 and has a history of 22 years and one month. Its registered office is in Indore, Madhya Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹3.16 Cr. The company has closed loans amounting to ₹4.95 M, as per Ministry of Corporate Affairs (MCA) records.
Rajesh Gangwani and Geeta Gangwani serve as directors at the Company.
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232MP2002PTC015469
- Company No.
015469
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Dec 2002
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Nikem Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Gangwani  | Director | 30-Dec-2002 | Current |
| Geeta Gangwani | Director | 30-Dec-2002 | Current |
Financial Performance of Nikem Drugs.
Nikem Drugs Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 20.74% increase. The company also saw a substantial improvement in profitability, with a 98.89% increase in profit. The company's net worth Soared by an impressive increase of 37.72%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nikem Drugs?
Unlock access to Nikem Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹31.60 M
₹4.95 M
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 3.02 Cr
- State Bank Of Saurashtra : 0.15 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Aug 2024 | Hdfc Bank Limited | ₹0.65 M | Open |
| 26 Sep 2017 | Hdfc Bank Limited | ₹1.60 Cr | Open |
| 11 Sep 2017 | Hdfc Bank Limited | ₹1.35 Cr | Open |
| 10 Sep 2003 | State Bank Of Saurashtra | ₹1.45 M | Open |
| 03 Apr 2006 | Union Bank Of India | ₹4.95 M | Satisfied |
How Many Employees Work at Nikem Drugs?
Nikem Drugs has a workforce of 5 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nikem Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nikem Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.